Literature DB >> 6192344

Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.

D M Evans, P D Minor, G S Schild, J W Almond.   

Abstract

The three serotypes of poliovirus are members of the picornaviradae, a group of viruses which cause a variety of diseases of considerable importance in man and animals. We have previously used antigenic mutants resistant to neutralizing monoclonal antibodies to identify a single antigenic site for the neutralization of poliovirus type 3 (ref. 1). Evidence based on oligonucleotide mapping suggested that this site corresponded largely to one physicochemical region of the capsid protein viral polypeptide 1 (VP1). We now present conclusive evidence that most of the mutations conferring resistance to neutralization are confined to an eight-amino acid region of VP1, specified by a sequence of viral RNA 277-300 bases from the start of the region coding for VP1. These data strongly suggest that this small region constitutes a major antigenic site involved in virus neutralization and they provide the most detailed information currently available on the antigenic site of a human virus.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6192344     DOI: 10.1038/304459a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  43 in total

1.  Molecular basis of antigenic structures of poliovirus: implications for their evolution during morphogenesis.

Authors:  K Wiegers; R Dernick
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Authors:  B Blondel; R Crainic; O Fichot; G Dufraisse; A Candrea; D Diamond; M Girard; F Horaud
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

3.  Very high frequency of reversion to guanidine resistance in clonal pools of guanidine-dependent type 1 poliovirus.

Authors:  J C de la Torre; E Wimmer; J J Holland
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

4.  Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.

Authors:  G D Westrop; K A Wareham; D M Evans; G Dunn; P D Minor; D I Magrath; F Taffs; S Marsden; M A Skinner; G C Schild
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

5.  High nucleotide substitution error frequencies in clonal pools of vesicular stomatitis virus.

Authors:  D A Steinhauer; J C de la Torre; J J Holland
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein.

Authors:  I Seif; P Coulon; P E Rollin; A Flamand
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

7.  Binding of neutralizing monoclonal antibodies to empty capsids of poliovirus can be blocked by monospecific antisera to structural polypeptides VP1 and VP2.

Authors:  H Uhlig; F Haardt; R Dernick
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

8.  Regions of poliovirus protein VP1 produced in Escherichia coli induce neutralizing antibodies.

Authors:  M E Hoatlin; O M Kew; M E Renz
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

9.  Evidence for at least two dominant neutralization antigens on human rhinovirus 14.

Authors:  B Sherry; R Rueckert
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

10.  Primary structure and gene organization of human hepatitis A virus.

Authors:  R Najarian; D Caput; W Gee; S J Potter; A Renard; J Merryweather; G Van Nest; D Dina
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.